Pavmed Inc (Pavmed) is a medical device company. It offers disposable infusion pumps, short-term catheters, percutaneous and tissue ablation devices, and long-term vascular access devices. Its products pipeline includes CarpX, a percutaneous device to treat carpal tunnel syndrome; PortIO, an implantable intraosseous vascular access device; and DisappEAR, an antimicrobial resorbable ear tube. Pavmed’s product pipeline also comprises NextCath, a self-anchoring catheter; NextFlo, a disposable infusion system; Caldus, a disposable tissue ablation device; EsoCheck, is a cell collection device; and EsoGuard, is an esophageal DNA test. The company has operations across US. Pavmed is headquartered in New York City, New York, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Pavmed Inc
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Table of Contents
- Pavmed Inc Company Overview
- Pavmed Inc Company Snapshot
- Pavmed Inc Pipeline Products and Ongoing Clinical Trials Overview
- Pavmed Inc - Pipeline Analysis Overview
- Pavmed Inc - Key Facts
- Pavmed Inc - Major Products and Services
- Pavmed Inc Pipeline Products by Development Stage
- Pavmed Inc Ongoing Clinical Trials by Trial Status
- Pavmed Inc Pipeline Products Overview
- Caldus - Renal Denervation
- Caldus - Renal Denervation Product Overview
- Caldus - Traditional Tissue Ablation
- Caldus - Traditional Tissue Ablation Product Overview
- DisappEAR
- DisappEAR Product Overview
- EsoCheck Cell Collection Device - Eosinophilic Esophagitis
- EsoCheck Cell Collection Device - Eosinophilic Esophagitis Product Overview
- EsoCure Esophageal Ablation Device
- EsoCure Esophageal Ablation Device Product Overview
- EsoGuard Test
- EsoGuard Test Product Overview
- EsoGuard Test Clinical Trial
- FlexMo
- FlexMo Product Overview
- Gen2 EsoCheck Balloon Sampling Device
- Gen2 EsoCheck Balloon Sampling Device Product Overview
- NextCath
- NextCath Product Overview
- NextFlo Intravenous Infusion Set
- NextFlo Intravenous Infusion Set Product Overview
- Non-Invasive Blood Glucose Measuring Device
- Non-Invasive Blood Glucose Measuring Device Product Overview
- Non-Invasive Diagnostic Test - BE Progression
- Non-Invasive Diagnostic Test - BE Progression Product Overview
- PortIO Device - Next Generation
- PortIO Device - Next Generation Product Overview
- PortIO Intraosseous Infusion System
- PortIO Intraosseous Infusion System Product Overview
- PortIO Intraosseous Infusion System Clinical Trial
- Pavmed Inc - Key Competitors
- Pavmed Inc - Key Employees
- Pavmed Inc - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Recent Developments
- Pavmed Inc, Recent Developments
- Aug 14, 2023: Lucid Diagnostics Provides Business Update and Second Quarter Financial Results
- Jun 02, 2023: Pavmed Digital Health Subsidiary, Veris Health, Joins Cancer Moonshot’s Cancerx Partnership as Founding Member
- May 16, 2023: PAVmed provides business update and Q1 financial results
- May 15, 2023: Lucid Diagnostics provides business update and Q1 financial results
- May 05, 2023: Lucid Diagnostics to hold a business update conference call and webcast on May 16, 2023
- May 05, 2023: PAVmed to hold a business update conference call and webcast on May 17, 2023
- Apr 19, 2023: PAVmed Digital Health subsidiary, Veris Health, to present comprehensive meta-analysis on impact of remote patient monitoring in oncology at HIMSS
- Mar 14, 2023: PAVmed Provides Business Update and Preliminary Fourth Quarter and Full Year 2022 Financial Results
- Mar 13, 2023: Lucid Diagnostics Provides Business Update and Fourth Quarter and Full Year 2022 Financial Results
- Feb 28, 2023: PAVmed Digital Health subsidiary Veris Health''s Veris Cancer Care Platform goes live
- Appendix
- Methodology
- About the Publisher
- Contact the Publisher
- Disclaimer
- Pavmed Inc Pipeline Products and Ongoing Clinical Trials Overview
- Pavmed Inc Pipeline Products by Equipment Type
- Pavmed Inc Pipeline Products by Indication
- Pavmed Inc Ongoing Clinical Trials by Trial Status
- Pavmed Inc, Key Facts
- Pavmed Inc, Major Products and Services
- Pavmed Inc Number of Pipeline Products by Development Stage
- Pavmed Inc Pipeline Products Summary by Development Stage
- Pavmed Inc Ongoing Clinical Trials by Trial Status
- Pavmed Inc Ongoing Clinical Trials Summary
- Caldus - Renal Denervation - Product Status
- Caldus - Renal Denervation - Product Description
- Caldus - Traditional Tissue Ablation - Product Status
- Caldus - Traditional Tissue Ablation - Product Description
- DisappEAR - Product Status
- DisappEAR - Product Description
- EsoCheck Cell Collection Device - Eosinophilic Esophagitis - Product Status
- EsoCheck Cell Collection Device - Eosinophilic Esophagitis - Product Description
- EsoCure Esophageal Ablation Device - Product Status
- EsoCure Esophageal Ablation Device - Product Description
- EsoGuard Test - Product Status
- EsoGuard Test - Product Description
- EsoGuard Test - A Multicenter Case-control Study of the Efficacy of EsoGuard on Samples Collected Using EsoCheck, Versus Esophagogastroduodenoscopy, for the Diagnosis of Barrett's Esophagus with and without Dysplasia, and for Esophageal Adenocarcinoma
- EsoGuard Test - A Multicenter, Prospective, Open-label Registry Study to Capture Real-world Data on Esoguard Testing in at-risk Patients for the Detection of Barrett's Esophagus or Esophageal Adenocarcinoma
- EsoGuard Test - Clinical Utility of a Non Endoscopic Device EsoCheck and Biomarker EsoGuard as Alternative to Endoscopy for Screening for Barrett's Esophagus in At Risk Population (ASBE) A Randomized Controlled, Virtual Patient Trial
- EsoGuard Test - CLUE: CLinical Utility Study of EsoGuard on Samples Collected Using EsoCheck as a Triage Test for Endoscopy to Identify Barrett's Esophagus (BE)
- EsoGuard Test - Detection of Barrett s Esophagus in Patients Without Gastroesophageal Reflux Disease (GERD) Symptoms
- EsoGuard Test - Genetic and Environmental Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma
- FlexMo - Product Status
- FlexMo - Product Description
- Gen2 EsoCheck Balloon Sampling Device - Product Status
- Gen2 EsoCheck Balloon Sampling Device - Product Description
- NextCath - Product Status
- NextCath - Product Description
- NextFlo Intravenous Infusion Set - Product Status
- NextFlo Intravenous Infusion Set - Product Description
- Non-Invasive Blood Glucose Measuring Device - Product Status
- Non-Invasive Blood Glucose Measuring Device - Product Description
- Non-Invasive Diagnostic Test - BE Progression - Product Status
- Non-Invasive Diagnostic Test - BE Progression - Product Description
- PortIO Device - Next Generation - Product Status
- PortIO Device - Next Generation - Product Description
- PortIO Intraosseous Infusion System - Product Status
- PortIO Intraosseous Infusion System - Product Description
- PortIO Intraosseous Infusion System - A First-in-human Clinical Safety Study of PortIO Implantation in Patients Requiring Infusion of Fluids or Medications
- PortIO Intraosseous Infusion System - First in Human Clinical Trial of the PAVmed PortIO Intraosseous Infusion System to Evaluate Safety and Performance
- Pavmed Inc, Key Employees
- Pavmed Inc, Subsidiaries
- Glossary
- Pavmed Inc Pipeline Products by Equipment Type
- Pavmed Inc Pipeline Products by Development Stage
- Pavmed Inc Ongoing Clinical Trials by Trial Status
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Avidity Biosciences Inc
- SINTX Technologies Inc
- KALA BIO Inc
- Advanced BioMedical Technologies, Inc.
- Atossa Therapeutics Inc
